ko 18 72
AUG 22 2007
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
SYNERON MEDICAL Ltd. VELASHAPE
This summary of safety and effectiveness information is being submitted in accordance
with the requirements of the SMDA 1990 and 21 CFR 807.92.
Submitter: Syneron Medical Ltd, Industrial Park, P.O.B. 550,
Yokneam IlLit, 20692, Israel.
Tel. +972-73-244-2200 ext. 591, Fax +972-73-244-2202
Name of the Device: VelaShape
Predicate Devices: This is special 510k for the VelaShape (name change from
VelaSmooth, Shaper) that is substantially equivalent to the
following cleared device: VelaSmooth, Shaper, manufactured by
Syneron Medical Ltd. and subject of K050397 and of K070092. |
Device Description: The VelaShape treatment is based on the simultaneous
application of heat and mechanical manipulation to the tissue,
wherein the heat is derived from light energy at a controlled
infrared wavelength and from conducted RF energy, and the
mechanical manipulation is derived from massage and/or
vacuum.
The VelaShape is indicated for the relief of minor muscle aches
and pain, relief of muscle spasm, temporary improvement of
local blood circulation, and temporary reduction in the ,
appearance of cellulite (K050397). The VelaShape is also
indicated for temporary reduction of thighs circumferences
(K070092).
The modification of the increased RF power of the VelaShape does not affect the
intended use or alter the fundamental scientific technology background of the device,
nor that it affect the mode of use. There are no labeling changes that affect the intended
use of the device.
The modification of the increased RF power raises no new issues of safety or
effectiveness.
t
August 16, 2007 o
Date Y6pi Iger, Ph.D.
Director of Clinical & Regulatory Affairs
Syneron Medical Ltd.

2 Le DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
vont Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850
Syneron Medical Ltd.
% Yoni Iger, Ph.D.
Director of Clinical & Regulatory
Affairs
Industrial Park
P.O. Box $50, Yokneam Illit AUG 22 2007
20692, Israel
Re: K071872
Trade/Device Name: VelaShape
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic surgery
and in dermatology
Regulatory Class: II
Product Code: NUV
Dated: July 4, 2007
Received: July 6, 2007
Dear Dr. Iger:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications for
use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce
prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that
have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic
Act (Act) that do not require approval of a premarket approval application (PMA). You may,
therefore, market the device, subject to the general controls provisions of the Act. The general
controls provisions of the Act include requirements for annual registration, listing of devices, good
manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class I (Special Controls) or class Il] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act :
or any Federal statutes and regulations administered by other Federal agencies. You must comply
with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part
807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the

Page 2 — Yoni Iger, Ph.D. :
quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product
radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
‘This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled,
“Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain other
general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
PER Mark N. td
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health
Inclosure

Indications for Use
510(k) Number (if known): K071872
Device Name: VelaShape
Indications for Use: :
The VelaShape is indicated for the relief of minor muscle aches and pain, relief of
muscle spasm, temporary improvement of local blood circulation, temporary reduction
in the appearance of cellulite, and for temporary reduction of thighs circumferences.
Prescription Use K Over-The-Counter Use
AND/OR
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE
. OF NEEDED)
Concurrence of hb of Device Evaluation (ODE)
(Division Sign-Off) .
Division of General, Restorative, Page 1 of 1
and Neurological Devices
WNE72
s10(k) Number__KO7'@72 _

